Table 1 Demographic and clinical data of patients studied

Gender ratio (male:female)

1.2:1

Age at time of study (in years mean ± SD)

13.7 ± 3.2

Age at onset of Crohn’s disease (in years mean ± SD)

12.2 ± 3.6

Disease duration (in months mean ± SD)

21.6 ± 21

Disease duration median number of months

15

Overall scores on PCDAI (mean ± SD)

11.5 ± 14.2

Overall scores on IMPACT-III index (mean ± SD)

103.5 ± 30

CRP (mg/L, mean ± SD)

11.8 ± 19.3

PLT count (10⁹, mean ± SD)

422 ± 145

 sulfasalazine/mesalamine

70/82 (85%)

 azathioprine

58/82 (70%)

 infliximab

16/82 (20%)

 methylprednisolone

16/82 (20%)

 budenoside

7/82 (9%)

 methotrexate

5/82 (6%)

 NSAID

3/82 (4%)